'Xtandi and Erleada' compete in the prostate cancer market
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.08.14 05:59:44
가나다라
0
Xtandi, a type of ARTA, is a leading product, generating KRW 14.1 billion in outpatient sales in the first half of the year
Erleada generated prescription sales of KRW 11.8 billion in the first half of the year…close to Xtandi's sales in Q2
Astellas has a competitive edge with Xtandi's broad indications…Janssen diversifies portfolio
The market for ARTA treatment used to treat prostate cancer has been dominated by Xtandi (enzalutamide). As prescription sales of Erleada (apalutamide) rise, the market is shifting.
Astellas Pharma's Xtandi has increased its competitiveness with its indications, Janssen has started to face competition by expanding its portfolio, including Erleada, Zytiga, and Akeega.
▲(From left) product photos of Erleada and Xtandi
According to the pharmaceutical market research firm UBIST, Xtandi generated the highest outpatient prescription sales in this year's first half, KRW 14.1 billion.
Analysis suggests that increased outpatient prescription sales are due to expanded reimbursement. In August 2022, Xtandi was selectively r
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)